Potential conflicts of interest. J. M. L. reports grants from Gilead Sciences and ViiV Healthcare; honoraria from Gilead Sciences, ViiV Healthcare, and Janssen-Cilag for educational presentations and events; serving as a member on the panel of the Spanish Antiretroviral Treatment Guidelines; consulting fees from ViiV Healthcare, Gilead Sciences, Janssen-Cilag, and Thera-Technologies; and support for attending meetings and/or travel from Gilead Sciences. D. A. R. K. reports research support and consulting honoraria from ViiV Healthcare, Gilead Sciences, and Merck; consulting honoraria from AbbVie, GSK, and Janssen outside the submitted work; grants from the National Institute of Allergy and Infectious Diseases paid to institution and unrelated to this work; payment or honoraria to author for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen and Gilead; payment to author for expert testimony from Gilead; and paid participation on a data and safety monitoring board or advisory board for GSK and ViiV. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.